Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Theravance Inc and GlaxoSmithKline Plc announces positive results from studies comparing ANORO ELLIPTA With SERETIDE DISKUS and ADVAIR DISKUS in Patients With COPD


Friday, 14 Mar 2014 08:00am EDT 

Theravance Inc and GlaxoSmithKline plc:Positive results from three phase III studies.Two studies comparing efficacy and safety of combination anticholinergic / long-acting beta2-adrenergic agonist, Anoro Ellipta with inhaled corticosteroid / long-acting beta2-adrenergic agonist combination, Advair Diskus and third comparing efficacy.Safety of Anoro Ellipta with Seretide Diskus 'FSC 500/50' in patients with chronic obstructive pulmonary disease (COPD) and no history of moderate to severe COPD exacerbations in the last year.In each of studies UMEC/VI achieved statistically improvement in lung function, measured as weighted mean forced expiratory volume in one second (wm FEV1) over 0-24 hours at the end of 12 week study (day 84), compared to either dose of FSC. 

Company Quote

1417.5
5.0 +0.35%
20 Aug 2014